Cystatin C in diabetics as a marker of mild renal insufficiency after CABG

Ann Thorac Cardiovasc Surg. 2011;17(3):277-82. doi: 10.5761/atcs.oa.10.01577.

Abstract

Purpose: The purpose of this study was to evaluate the accuracy of plasma cystatin C in acute impairment in renal function; plasma cystatin C was compared to plasma creatinine in two hundred patients undergoing elective CABG surgery.

Methods: We performed a prospective clinical study of two hundred patients undergoing coronary bypass surgery. Plasma creatinine and cystatin C were measured preoperatively and on the first and fourth days after surgery. Estimated glomerular filtration rate (GFR) was calculated using one creatinine-based and two cystatin C-based equations.

Results: There were 144 non-diabetic and 56 diabetic patients. The need for furosemide was more common among diabetics (80.4% of the patients vs. 53.9%, p = 0.024). Changes in cystatin C-based GFR with both equations were significantly greater in the group of diabetics (-14.3 ± 28.0 and -11.2 ± 19.3 ml/min/1.73 m(2) vs. -4.3 ± 26.9 and -3.1 ± 20.5 ml/min/1.73 m(2), p = 0.025 and 0.016, respectively). Changes in creatinine-based GFR did not differ between the diabetics and the non-diabetics.

Conclusion: Cystatin C and cystatin C-based estimation of GFR may be useful and more sensitive than creatinine in detecting mild acute renal insufficiency in diabetic patients.

Publication types

  • Comparative Study

MeSH terms

  • Acute Kidney Injury / blood
  • Acute Kidney Injury / diagnosis*
  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / physiopathology
  • Aged
  • Biomarkers / blood
  • Chi-Square Distribution
  • Coronary Artery Bypass / adverse effects*
  • Creatinine / blood*
  • Cystatin C / blood*
  • Diabetes Mellitus / diagnosis*
  • Diuretics / therapeutic use
  • Elective Surgical Procedures
  • Finland
  • Furosemide / therapeutic use
  • Glomerular Filtration Rate
  • Humans
  • Middle Aged
  • Predictive Value of Tests
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • CST3 protein, human
  • Cystatin C
  • Diuretics
  • Furosemide
  • Creatinine